Story perspectives

Vertex's CRISPR Therapy Shows Promise for Sickle Cell Kids

12/6/2025

47 3

Summary

Story summary

On December 6, 2025, Vertex announced Casgevy, a CRISPR-based gene therapy, showing promising results for children aged 5–11 with sickle cell disease.
Findings presented at the American Society of Hematology Annual Meeting show 12-month vaso-occlusive-crisis freedom for these children.
Transfusion-dependent beta-thalassemia (TDT) patients have achieved transfusion-free status for up to two years, though one patient died from pre-transplant complications.
Vertex plans to file for regulatory approval in early 2026.

1 of 1

Story summary

On December 6, 2025, Vertex announced Casgevy, a CRISPR-based gene therapy, showing promising results for children aged 5–11 with sickle cell disease.
Findings presented at the American Society of Hematology Annual Meeting show 12-month vaso-occlusive-crisis freedom for these children.
Transfusion-dependent beta-thalassemia (TDT) patients have achieved transfusion-free status for up to two years, though one patient died from pre-transplant complications.
Vertex plans to file for regulatory approval in early 2026.